NCT06023134
Clinical Characteristics and Outcomes of Patients With Pulmonary Hypertension Associated Right Heart Failure
At risk: Primary completion moved 2 years later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 2 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Sep 1, 2025 to Sep 1, 2027
- Eligibility criteria expanded, about 8 words
- Study completion pushed from Dec 1, 2025 to Dec 1, 2027
- Secondary endpoints: details revised at 2 of 11 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (11)
Show 6 moreShow less
Arms and interventions
Participants met the indication for right heart catheterization but did not meet the diagnostic criteria for pulmonary hypertension and right heart failure.
Participants were classified according to the 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension, meaning that a mean pulmonary artery pressure (mPAP) ≥20 mmHg was defined as PH.
Right heart failure was considered present when RV fractional area change (FAC) was \<35% or tricuspid annular systolic velocity (RV S') was \<9.5 cm/s or tricuspid annular plane systolic excursion (TAPSE) \<17mm.
Diagnostic tests: Echocardiography, Right heart catheterization
Sites
1 site in 1 country
- China-Japan Friendship HospitalBeijing, Beijing Municipality, China